A study to identify a possible inhibitory effect of a CBD derivative to inhibit Allergic Airway Inflammation / Asthma

Allergic inflammation (AI). Allergic diseases, including asthma/allergic airway inflammation (AAI), allergic rhinitis, atopic dermatitis and food allergy affecting ~20% of the global population are continually increasing. These are all chronic inflammatory processes, characterised by IgE mediated mast cell (MCs) activation through the FcεRI bound allergen and subsequent eosinophil (Eos) infiltration.

Most of the allergic disease patients’ symptoms are controlled by either symptomatic drugs or corticosteroids. Nevertheless, some patients, such as those suffering from severe asthma, are usually steroid-resistant and therefore allergic diseases such as severe asthma and atopic dermatitis have been labeled as unmet clinical needs by the WHO.

As CBD has been shown to be a potent anti-inflammatory agent and to affect asthma in rodent models we will examine whether our test compound also affects this disease and whether MCs and Eos are directly influenced by it. Since MCs and Eos are the main effectors in AAI, we will examine the direct effect of cannabinoids on these two cell types; MCs and Eos.

In asthma as in the other allergic diseases, MCs release inflammatory mediators to orchestrate the immediate-early phase of the response that is usually followed by a late phase response characterized by the recruitment and activation of several inflammatory cells, and notably by the Eos (bone marrow-derived, blood resident granulocytes that respond to MC-released mediators and appear to play pivotal roles in the nature and extent of airway inflammatory responses together with other innate and adaptive immune cells. When MCs and Eos are activated, several preformed (e.g.histamine from MCs, granular basic mediators from Eos) and newly synthesized (e.g., lipid) mediators and cytokines/chemokines are released. Both Eos and MCs have a “lead” role in allergic reactions but are also involved in host-defense responses, cancer autoimmune diseases, and tissue repair/fibrosis and pro-angiogenic processes.

Following the completion of these experiments, we will know whether our cannabinoid will affect the AAI and whether it has the potential to directly downregulate the pro-inflammatory functions of MCs and Eos

1. Gangwar RS, Landolina N, Arpinati L, Levi-Schaffer F. Mast cell and eosinophil surface
receptors as targets for anti-allergic therapy. Pharmacol Ther.2017; 170:37-63.
2. Braunstahl GJ, Hellings PW. Allergic rhinitis and asthma: the link further unraveled. Curr Opin
Pulm Med. 2003; 1:46-51.
3. KleinJan A, Willart M, van Nimwegen M, Leman K, Hoogsteden HC, Hendriks RW, et al. United
airways: circulating Th2 effector cells in an allergic rhinitis model are responsible for promoting
lower airways inflammation. Clin Exp Allergy. 2010;40:494-504.
4. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012; 18:693-704


Follow us and enjoy up to date information on the medical cannabis industry together with cannabinoid research and product development.